Here’s what you should know.
1. Analysts projected $1.37 earnings per share in the third quarter. Stryker posted $1.39 earnings per share.
2. Stryker had $2.83 billion in revenue, a 23.96 percent return on net equity and a 15.24 percent net margin.
3. Quarterly revenue was up 17.1 percent on a year-over-year basis.
4. When it comes to market analysts, 12 gave Stryker a “buy” rating, nine a “hold” rating and three rated it as a “sell.”
More articles on orthopedics/spinal devices:
DePuy Synthes, Mazor, NuVasive & more: 20 key notes — NASS edition
DePuy Synthes unveils Zero-Profile Plate for spinal fusions: 5 things to know
Zimmer Biomet acquires RespondWell to strengthen home rehabilitation offering: 4 points
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
